WHEN TO CONSIDER XCOPRI

Are your epilepsy patients still experiencing seizures? It may be time to consider XCOPRI

AN ESTABLISHED ANTI-SEIZURE MEDICATION (ASM) DELIVERING ON THE POSSIBILITY OF ZERO1

hidden

#1

prescribed by Epileptologists for new branded ASMs2⁠*

XCOPRI Orange Tablet Icon

0

patients
on treatment2†

Red XCOPRI Patient Icon

0

prescriptions written to date for XCOPRI2‡

Prescription Pad Icon

3+

years since
FDA approval1

Red Calendar Icon

0‡ XCOPRI® (cenobamate tablets) CV prescriptions have been written for 0 patients2†

* By NBRx as of June 2023.
†Worldwide new-to-brand cenobamate prescriptions as of December 2023.
‡Total US prescriptions as of December 2023.

ZERO

As many as 1 in 5 patients experienced
ZERO seizures during the maintenance
phase when taking XCOPRI1

See Data

XCOPRI can be prescribed
as monotherapy
or adjunctive therapy1

Learn How

Flexible, once-daily dosing to take patients through their treatment journey1

View Dosing
References: 1. XCOPRI [Package Insert]. Paramus, NJ: SK Life Science, Inc. 2. Data on file, IQVIA December 2023. SK Life Science, Inc.

MOA

XCOPRI reduces neuronal excitability through a dual mechanism of action1*

XCOPRI MOA Y-Aminobutyric Acid (GABA) Ion Channel Model

Positive Allosteric Modulator of the GABAA Receptor

Potentiates GABAA-receptor inhibition by enhancing the inward movement of chloride ions.1-3

XCOPRI MOA Voltage-Gated Sodium Currents Model

Inhibits Persistent Sodium Current

Reduces repetitive neuronal firing by inhibiting the persistent component of the inward sodium current.1,4

XCOPRI IN ACTION

See how XCOPRI partial-onset seizure treatment may fit into your patients’ lives

View Dosing
*The precise mechanism by which XCOPRI exerts its anticonvulsant activity is unknown.1
References: 1. XCOPRI [Package Insert]. Paramus, NJ: SK Life Science, Inc. 2. Sharma R, Song WS, Nakamura M, et al. Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate. Eur J Pharmacol. 2020;879:173117. doi:10.1016/j.ejphar.2020.173117. 3. Mihic S.J., Harris RA. GABAA and the GABA receptor. Alcohol Health Res World. 1997;21(2):127-131. 4. Nakamura M, Cho J-H, Shin H, Jang I-S. Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rate hippocampal CA3 neurons. Eur J Pharmacol. 2019;855:175-182. doi: 10.1016/j.ejphar.2019.05.007.
Expand

INDICATION

XCOPRI® (cenobamate tablets) CV is indicated for the treatment of partial‑onset seizures in adult patients.

Important Safety Information
and indication

CONTRAINDICATIONS
XCOPRI® is contraindicated in any patients with known hypersensitivity to the compound or any of the components of the drug product.
XCOPRI is contraindicated in patients with Familial Short QT syndrome.

‑
Close IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION and INDICATION for XCOPRI® (cenobamate tablets) CV

CONTRAINDICATIONS

XCOPRI is contraindicated in any patients with known hypersensitivity to the compound or any of the components of the drug product.

XCOPRI is contraindicated in patients with Familial Short QT syndrome.

WARNINGS AND PRECAUTIONS

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Also known as Multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including XCOPRI. DRESS has been reported, including one fatality, when XCOPRI is titrated rapidly (weekly or faster titration). No cases of DRESS were reported in an open-label safety study of 1339 partial-onset seizure patients when XCOPRI was initiated at 12.5 mg/day and titrated every two weeks. This finding does not establish that the risk of DRESS is prevented by a slower titration; however, XCOPRI should be initiated at 12.5 mg once daily and titrated every two weeks. DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement. Eosinophilia is often present. If such signs or symptoms are present, the patient should be evaluated immediately. XCOPRI should be discontinued immediately and not restarted if an alternative etiology for the signs or symptoms cannot be established.

QT Shortening: XCOPRI can cause shortening of the QT interval. Caution should be used when administering XCOPRI and other drugs that shorten the QT interval as there may be a synergistic effect on the QT interval that would increase the QT shortening risk.

Suicidal Behavior and Ideation: Antiepileptic drugs (AEDs), including XCOPRI, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Advise patients, their caregivers, and/or families to be alert for these behavioral changes and report them immediately to a healthcare provider.

Neurological Adverse Reactions: XCOPRI causes dose-dependent increases in the neurologic adverse reactions including, dizziness, diplopia, disturbance in gait and coordination, somnolence, and fatigue.

Prescribers should advise patients against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous machinery, until the effect of XCOPRI is known.

Withdrawal of AEDs: As with all antiepileptic drugs, XCOPRI should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus. But if withdrawal is needed because of a serious adverse event, rapid discontinuation can be considered.

MOST COMMON ADVERSE REACTIONS

In adult adjunctive therapy placebo-controlled clinical studies, the most common adverse reactions that occurred in XCOPRI-treated patients (incidence at least 10% and greater than placebo) were somnolence, dizziness, fatigue, diplopia, headache.

DOSING CONSIDERATIONS

Dosage adjustment of XCOPRI or other concomitant medications may be necessary.

  • Consider gradually reducing phenytoin dosages by up to 50% during initial titration.
  • Consider reducing dosages of phenobarbital and clobazam as needed when used concomitantly with XCOPRI. When XCOPRI and carbamazepine or lamotrigine are taken concomitantly, consider increasing dosages as needed of carbamazepine or lamotrigine.
  • Consider increasing dosages as needed of drugs which are CYP2B6 and CYP3A substrates and decreasing dosages as needed of drugs which are CYP2C19 substrates.
  • Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control.

Dosage reduction of XCOPRI may be considered in patients with mild to moderate and severe renal impairment. XCOPRI use is not recommended in end‑stage renal disease.

The maximum recommended daily dose is 200 mg for patients with mild or moderate hepatic impairment. XCOPRI use is not recommended in patients with severe hepatic impairment

DRUG ABUSE

XCOPRI is a Schedule V controlled substance.

INDICATION

XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.

Please see full Prescribing Information.